[go: up one dir, main page]

WO2022163989A1 - Composition pour prévenir ou réduire la chute des cheveux, comprenant un gène ou une protéine de collagène - Google Patents

Composition pour prévenir ou réduire la chute des cheveux, comprenant un gène ou une protéine de collagène Download PDF

Info

Publication number
WO2022163989A1
WO2022163989A1 PCT/KR2021/017480 KR2021017480W WO2022163989A1 WO 2022163989 A1 WO2022163989 A1 WO 2022163989A1 KR 2021017480 W KR2021017480 W KR 2021017480W WO 2022163989 A1 WO2022163989 A1 WO 2022163989A1
Authority
WO
WIPO (PCT)
Prior art keywords
hair loss
composition
dermal papilla
col13a1
col15a1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2021/017480
Other languages
English (en)
Korean (ko)
Inventor
김현주
최나현
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epi Biotech Co Ltd
Original Assignee
Epi Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epi Biotech Co Ltd filed Critical Epi Biotech Co Ltd
Publication of WO2022163989A1 publication Critical patent/WO2022163989A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Definitions

  • the present invention relates to a composition for preventing or improving hair loss comprising a COL13A1, COL15A1 or COL23A1 gene or fragment.
  • the present invention relates to a composition for preventing or improving hair loss comprising collagen alpha-1 (XIII), and collagen alpha-1 (XV) or collagen alpha-1 (XXIII) protein, or a fragment thereof.
  • Hair goes through a three-stage cycle of anagen, catagen, and telogen, where it grows, maintains, and falls out.
  • the growth period which is the period of hair growth
  • hair grows on average about 0.3 mm per day, grows about 1 cm per month, and it is known that it usually lasts for 3 to 7 years.
  • overall hair follicle cell apoptosis apoptosis
  • hair follicles shrink during the catagen phase which is a phase in which the hair follicles are reduced
  • the telogen phase which is a phase to prepare for the next growth phase with an average of 3 months.
  • the hair falls out after passing through, and the reason the length of the hair is different depending on the part is that the duration of the growth phase, which is a unique characteristic of the hair follicle, is different for each part.
  • human hair always maintains a certain number of hairs because it has a constant hair growth cycle.
  • the dermal papilla present in the hair root becomes smaller, and when the dermal papilla becomes smaller, the thickness of the hair becomes thinner and the hair growth cycle is shortened at the same time. Therefore, as hair loss progresses, the hair becomes very thin, and the hair growth cycle becomes shorter and falls out after a little growth.
  • Human hair is an aggregate of about 100,000 individual hairs, and hair is produced by hair follicles.
  • the hair follicle serves as a repository of stem cells capable of generating all the cell lines needed to reconstitute the hair follicle itself, the epithelium and the sebaceous glands.
  • Hair follicles are composed of dermal papilla cells (DPC), hair germinal matrix cells, outer root sheath cells (ORS), and inner root sheath cells (IRS).
  • the outer root sheath cells are cells that help the growth and development of hair and protect the hair, and are in contact with the basal layer, the innermost layer of the epidermis. Together with the inner hair root sheath, it protects the hair generated from the hair bulb, the lower part of the hair follicle, until the keratinization is completed, and transports it to the epidermis.
  • Outer root sheath cells are created by cell division near the hair bulb, transport hair to the epidermis and fall off from the scalp after fulfilling its role.
  • the dermal papilla cells are the core cells responsible for the development and growth of hair, and are located at the bottom of the hair root, which is the subcutaneous root of the hair. In fact, when dermal papilla cells are collected from the scalp and transplanted after culturing, new hair grows. However, there are several difficulties in using dermal papilla cells as a treatment for hair loss. First, it is difficult to separate from the scalp, the culture conditions are difficult, and it is difficult to culture a sufficient amount of cells. In addition, there is a limit in that the hair regeneration ability is significantly reduced when a lot of culture.
  • the present inventors confirmed that a large amount of collagen is expressed in the dermal papilla cells of the growth phase, but that the expression of collagen is decreased in both flow cells of the degenerative phase, and completed the present invention for the prevention and improvement of hair loss using collagen genes and proteins. .
  • Patent Document 1 Korean Patent No. 10-2069184
  • Patent Document 2 Korean Patent No. 10-0841923
  • Patent Document 3 Korean Patent No. 10-0841920
  • An object of the present invention is to prevent or improve hair loss by increasing collagen genes or proteins in dermal papilla cells to prevent aging of dermal papilla cells and to promote hair regeneration.
  • an object of the present invention is to diagnose hair loss by examining the content of collagen gene or protein in dermal papilla cells.
  • the present invention provides a composition for preventing or improving hair loss comprising the COL13A1, COL15A1 or COL23A1 gene, or a fragment thereof.
  • the present invention provides a composition for preventing or improving hair loss comprising a protein encoded by a COL13A1, COL15A1 or COL23A1 gene, or a fragment thereof.
  • the present invention provides a composition for preventing or improving hair loss comprising collagen alpha-1 (XIII), and collagen alpha-1 (XV) or collagen alpha-1 (XXIII) protein, or a fragment thereof.
  • the composition of the present invention may be a pharmaceutical composition or a cosmetic composition.
  • composition of the present invention may be administered orally or parenterally, and when administered parenterally, it may be administered intravenously, subcutaneously, intramuscularly, intraperitoneally, transdermally, etc., preferably in the form of a hair filler.
  • the present invention provides a food composition for preventing or improving hair loss comprising collagen alpha-1 (XIII), and collagen alpha-1 (XV) or collagen alpha-1 (XXIII) protein, or a fragment thereof.
  • the present invention provides a method for diagnosing hair loss comprising detecting a COL13A1, COL15A1 or COL23A1 gene from a biological sample of a subject.
  • the present invention may further comprise the step of diagnosing the degree and possibility of hair loss of the subject by comparing the amount of the gene measured from the biological sample of the subject with the amount of the gene measured from the biological sample of the normal control group.
  • the present invention provides a method for diagnosing hair loss comprising detecting collagen alpha-1 (XIII), collagen alpha-1 (XV) or collagen alpha-1 (XXIII) protein from a biological sample of a subject.
  • the present invention may further include the step of diagnosing the degree and possibility of hair loss of the subject by comparing the amount of the protein measured from the biological sample of the subject with the amount of the protein measured from the biological sample of the normal control group.
  • the biological sample may be cells, tissues, blood, whole blood, serum, plasma, saliva, sputum, cerebrospinal fluid, urine, or feces, preferably dermal papilla cells.
  • composition comprising the COL13A1, COL15A1 or COL23A1 gene, or a fragment thereof according to the present invention has the effect of preventing the aging of dermal papilla cells and enhancing hair regeneration, and thus can be usefully used to improve or prevent hair loss.
  • composition comprising collagen alpha-1 (XIII), collagen alpha-1 (XV) or collagen alpha-1 (XXIII) protein, or a fragment thereof according to the present invention prevents aging of dermal papilla cells and improves hair regeneration It can be usefully used to improve or prevent hair loss by having the effect of
  • the collagen gene or protein in the dermal papilla cells can be used to diagnose the degree or possibility of hair loss.
  • Figure 2 shows the levels of p16 mRNA and p21 mRNA according to the number of passages of dermal papilla cells.
  • Figure 3 shows the level of aggregation according to the number of passages of dermal papilla cells.
  • Figure 4 shows the hair-generating ability according to the number of passages of dermal papilla cells.
  • FIG. 5 shows the mRNA levels of COL13A1, COL15 and COL23A1 according to the number of passages of dermal papilla cells.
  • FIG. 6 shows the protein expression levels of COL13A1, COL15A1 and COL23A1 according to the number of passages of dermal papilla cells.
  • FIG. 7 shows the mRNA levels of COL13A1 and COL15A1 in Col13A1 and Col15A1 knockout dermal papilla cells.
  • FIG. 8 shows the protein expression levels of COL13A1 and COL15A1 in Col13A1 and Col15A1 knockout dermal papilla cells.
  • FIG. 11 shows the cell numbers of Col13A1 and Col15A1 knockout dermal papilla cells.
  • FIG. 13 shows the levels of p16 mRNA and p21 mRNA in Col13A1 and Col15A1 knockout dermal papilla cells.
  • 17 shows the mRNA levels of TGF- ⁇ 1 and TGF- ⁇ 2 in dermal papilla cells.
  • 21 shows the PDL levels of dermal papilla cells upon treatment with TGF- ⁇ 2.
  • hair loss refers to a state in which there is no hair in a site where hair should normally exist, regardless of the cause, and alopecia areata, hereditary androgen alopecia, telogen alopecia, traumatic hair loss, hair growth wall, compressive It may be alopecia, anagen phase hair loss, alopecia pityis, syphilitic hair loss, seborrheic hair loss, symptomatic hair loss, scarring hair loss, or congenital hair loss, but is not limited thereto.
  • collagen alpha-1 (XIII) refers to a protein encoded by the COL13A1 gene.
  • COL13A1 encodes the alpha chain of one of the non-fibrous collagens and undergoes a complex and extensive splicing process involving at least 8 exons.
  • the function of the gene product, collagen alpha-1 (XIII) is unknown, but it is detected at low levels in all connective tissue-producing cells and can function normally in connective tissue.
  • collagen alpha-1 (XIII) contains a transmembrane domain, so that the protein is confined to the plasma membrane.
  • Collagen alpha-1 (XIII) belongs to the transmembrane collagen subgroup, such as collagen XIII, XXIII, and XXV.
  • collagen alpha-1 (XV) refers to a protein encoded by the COL15A1 gene.
  • COL15A1 encodes an alpha chain of type XV collagen, one of the FACIT (Fibril-Associated Collagens with Interrupted Triple Helices) collagen family.
  • Collagen alpha-1 (XV) may function to attach the basement membrane to the basal connective tissue, and may serve as membrane support and cell anchorage.
  • collagen alpha-1 (XV) deficiency is associated with muscle and microvascular deterioration.
  • collagen alpha-1 (XV) is known as a tumor suppressor that can be used to understand the tumor cell environment, and changes in collagen alpha-1 (XV) are known to induce cancer-like behavior in tissues.
  • Collagen alpha-1 (XXIII) refers to a protein encoded by the COL23A1 gene. It is located on chromosome 5q35 in humans and on chromosome 11B1 + 2 in mice. Collagen alpha-1 (XXIII) is a type II transmembrane protein and belongs to a subgroup of non-fibrous collagen. This type of collagen has a single passage hydrophobic transmembrane domain. Collagen alpha-1 (XXIII) is expressed in both adult tissues and organs of development, and can be found in other epitheliums such as the epidermis, tongue, intestine and lungs, as well as in the brain, kidney and cornea. The function of collagen alpha-1 (XXIII) is not yet known, but it is known to be similar to other transmembrane proteins.
  • prevention refers to any action that suppresses or delays the onset of a disease by administration of the composition
  • treatment means that the symptoms of the suspected disease and the onset individual are improved or beneficially changed by administration of the composition It means any action that causes a condition, and amelioration means any action that at least reduces a parameter related to a condition, for example, the severity of a symptom by administration of the composition.
  • composition of the present invention may be administered orally or parenterally, and when administered parenterally, it may be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, or the like.
  • the pharmaceutical composition of the present invention can be prepared according to a conventional method according to a conventional method, such as powders, granules, tablets, soft or hard capsules, suspensions, emulsions, syrups, oral formulations such as aerosols, external preparations for skin such as ointments, creams, suppositories, injections, It may be formulated and used in any form suitable for the preparation, including fillers and sterile injection solutions.
  • the cosmetic composition of the present invention is formulated in the form of a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, spray, or filler.
  • a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing oil, powder foundation, emulsion foundation, wax foundation, spray, or filler.
  • the "hair filler" of the present invention is a form that can be used by directly injecting it into the scalp through injection, has few side effects and has the advantage of exhibiting the effect of rapid hair loss prevention or improvement.
  • the injection amount and the number and shape of injection needles can be changed.
  • the food composition of the present invention may be a health functional food, dairy product, fermented product or food additive.
  • the food composition comprises various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavoring agents, coloring agents and thickening agents (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and It may further include salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like.
  • flavoring agents such as synthetic and natural flavoring agents, coloring agents and thickening agents (cheese, chocolate, etc.
  • pectic acid and its salts alginic acid and It may further include salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like.
  • the food composition includes the form of pills, powders, granules, needles, tablets, capsules, liquids, pastes, gels, or jellies, and the food to which the composition can be added includes, for example, There are various foods, for example, beverages, gum, tea, vitamin complexes, health supplements, and the like.
  • the formulation of the food composition is not particularly limited, but, for example, may be formulated as tablets, granules, powders, liquids such as drinks, caramel, gels, bars, and the like.
  • the food composition of each dosage form can be formulated without difficulty by those skilled in the art without difficulty depending on the dosage form or purpose of use of ingredients commonly used in the field.
  • SA- ⁇ -Gal staining was performed as follows.
  • the cell membrane was lysed using Trizol reagent. Then, 1/5 volume (volume) of chloroform (chloroform) solution was added and mixed vigorously using a vortex for 10 seconds. The well-mixed solution was centrifuged for 15 minutes at 14,000 rpm at 4°C. Then, the upper layer of the solution divided into two layers was obtained, and the same volume of isopropanol was added and stored at -20°C for at least 30 minutes.
  • chloroform chloroform
  • cDNA was synthesized with 50 ng/ ⁇ l of oligo (dT) primer, 10 mM dNTP, and 10,000 U of reverse transcriptase.
  • the expression levels of senescence-related genes p16 and p21 were analyzed through the qRT-PCR method using the cDNA and the primers shown in Table 1 below.
  • SEQ ID NO: 1 sense 5'-CTCGTGCTGATGCTACTGAGGA-3'
  • SEQ ID NO: 2 antisense 5'-GGTCGGCGCAGTTGGGCTCC-3'
  • SEQ ID NO: 3 sense 5'-AGGTGGACCTGGAGACTCTCAG-3'
  • SEQ ID NO: 4 antisense 5'-TCCTCTTGGAGAAGATCAGCCG-3'
  • EPC epidermal cells
  • dermal papilla cells passages 5 and 13 with different number of passages were mixed with the dermal papilla cell aggregates (about 100 dermal papilla cell aggregates) cultured by the above method with 1 x 10 6 epidermal cells, and 6-week-old female nude mice (BALB) /cAJcl-nu) was subcutaneously implanted on the back.
  • Dermal cells mixed with neonatal mouse epidermal cells were used as a control. After 3 weeks of implantation, the dissected samples were imaged through a microscope.
  • FIGS. 3 and 4 The experimental results are shown in FIGS. 3 and 4 . As shown in Figure 3, it was confirmed that the cell cohesiveness of the dermal papilla cells with an increased number of subcultures was significantly reduced. In addition, as shown in FIG. 4 , it was confirmed that the hair production ability decreased when the number of subcultures of dermal papilla cells increased.
  • Col13A1 SEQ ID NO: 5 sense 5'-TGGAGAACAGGGACCAGATGGC-3' SEQ ID NO: 6 antisense 5'-GATCTCCTGGAGAGCCTCATTG-3' Col15A1 SEQ ID NO: 7 sense 5'-GGTGACACTGGTTTACCTGGCT-3' SEQ ID NO: 8 antisense 5'-GCCTTTCCAGAGGAATGTCCTC-3'
  • FIGS. 5 and 6 The experimental results are shown in FIGS. 5 and 6 .
  • FIG. 5 it was confirmed that the mRNA levels of COL13A1, COL15A1 and COL23A1 decreased when the number of subcultures of dermal papilla cells increased.
  • FIG. 6 it was confirmed that when the number of subcultures of dermal papilla cells increased, the protein expression of COL13A1 and COL15A1 also decreased.
  • COL13A1 siRNA (Serrin Bioneer Science, 1305-1) and COL15A1 siRNA (Serine Bioneer Science, 1306-1) were commissioned and manufactured by Serin Bioscience (Gyeonggi-do, Korea).
  • siRNA using an siRNA introduction reagent (Lipofectamin RNAiMAX Transfection Reagent, Invitrogen), according to the manufacturer's instructions, the dermal papilla cells of the fourth passage were injected and transformed.
  • the transformed cells were cultured in the same manner as in Example 3, and real time PCR and immunofluorescence staining were performed for COL13A1 and COL15A1.
  • FIGS. 7 and 8 The experimental results are shown in FIGS. 7 and 8 .
  • FIG. 7 it was confirmed that the mRNA levels of Col13A1 and Col15A1 were decreased in Col13A1 and Col15A1 knockout dermal papilla cells compared to the control group.
  • FIG. 8 it was confirmed that the protein expression of Col13A1 and Col15A1 was decreased in Col13A1 and Col15A1 knockout dermal papilla cells compared to the control group.
  • FIGS. 9 and 10 The experimental results are shown in FIGS. 9 and 10 . As shown in FIG. 9 , it was confirmed that the cohesive force of Col13A1 and Col15A1 knockdown dermal papilla cells was decreased. In addition, as shown in FIG. 10 , it was confirmed that the hair-producing ability of Col13A1 and Col15A1 knockdown dermal papilla cells was reduced.
  • Transfection by injecting COL13A1 siRNA (25 nM) and COL15A1 siRNA (25 nM) into dermal papilla cells of passage 4 (2 x 10 5 ) using siRNA introduction reagent (Lipofectamin RNAiMAX Transfection Reagent, Invitrogen) according to the manufacturer's instructions converted. Transformed cells were cultured in dermal papilla cell culture medium for 48 hours. After mixing trypan blue and cells in a ratio of 9: 1, the number of cells was measured using a hematocyte.
  • siRNA introduction reagent Lipofectamin RNAiMAX Transfection Reagent, Invitrogen
  • the collected skin tissue was fixed in 10% formalin to prepare paraffin sections.
  • the prepared slides were deparaffinized and rehydrated, and rabbit COL13A1 (MybioSource), rabbit COL15A1 (MybioSource), and Alexa Fluor 488 goat anti-rabbit immuglobulin G (IgG) (Invitrogen) antibodies were used. This was observed with a confocal microscope.
  • FIGS. 14 to 16 The experimental results are shown in FIGS. 14 to 16 .
  • FIG. 14 it was confirmed that SA- ⁇ -Gal staining was increased in the dermal papilla part of aging mice.
  • FIGS. 15 and 16 it was confirmed that the expression of Col13A1 and Col15A1 was reduced in senescent mouse dermal papilla cells.
  • FIGS. 18 to 21 The experimental results are shown in FIGS. 18 to 21 .
  • FIG. 18 it was confirmed that the cohesive force of dermal papilla cells was increased by TGF- ⁇ 2 treatment.
  • FIG. 19 it was confirmed that the levels of Col13A1 and Col15A1 mRNA increased upon TGF- ⁇ 2 treatment, and as shown in FIG. 20 , it was confirmed that the protein expression of Col13A1 and Col15A1 also increased upon TGF- ⁇ 2 treatment. did.
  • FIG. 21 it was confirmed that the level of PDL significantly increased when TGF- ⁇ 2 was treated.
  • RNA extraction from the 11 passage dermal papilla cell aggregates cultured in the same manner as in Example 12 p16 and p21 mRNA expression was quantified by qRT-PCR method.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Birds (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Nutrition Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

La présente invention concerne une composition pour prévenir ou réduire la chute des cheveux comprenant un gène COL13A1, COL15A1 ou COL23A1 ou un fragment de celui-ci. De plus, la présente invention concerne une composition pour prévenir ou réduire la chute des cheveux, comprenant la protéine de collagène alpha-1 (XIII), et la protéine de collagène alpha-1 (XV) ou de collagène alpha-1 (XXIII), ou un fragment de celle-ci.
PCT/KR2021/017480 2021-01-27 2021-11-25 Composition pour prévenir ou réduire la chute des cheveux, comprenant un gène ou une protéine de collagène Ceased WO2022163989A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2021-0011810 2021-01-27
KR1020210011810A KR102298460B1 (ko) 2021-01-27 2021-01-27 콜라겐 유전자 또는 단백질을 포함하는 탈모의 예방 또는 개선용 조성물

Publications (1)

Publication Number Publication Date
WO2022163989A1 true WO2022163989A1 (fr) 2022-08-04

Family

ID=77787741

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2021/017480 Ceased WO2022163989A1 (fr) 2021-01-27 2021-11-25 Composition pour prévenir ou réduire la chute des cheveux, comprenant un gène ou une protéine de collagène

Country Status (2)

Country Link
KR (1) KR102298460B1 (fr)
WO (1) WO2022163989A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102298460B1 (ko) * 2021-01-27 2021-09-08 주식회사 에피바이오텍 콜라겐 유전자 또는 단백질을 포함하는 탈모의 예방 또는 개선용 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009161509A (ja) * 2008-05-21 2009-07-23 Kanazawa Univ Ｘｖｉｉ型コラーゲンに関する脱毛抑制剤、毛髪の脱色素化抑制剤
KR20120089236A (ko) * 2009-07-23 2012-08-09 아데란스 리서치 인스티튜트 인코포레이티드 트리코겐성 진피세포 검출/강화 방법과 세포 및 탈모 치료법에의 사용
KR20130117260A (ko) * 2012-04-18 2013-10-25 경북대학교 산학협력단 남성형 탈모 진단용 바이오마커 조성물 및 이를 이용한 진단 방법
JP2018168166A (ja) * 2016-01-12 2018-11-01 国立大学法人 東京医科歯科大学 脱毛および白毛化を抑制もしくは改善するための組成物ならびにその使用
KR102298460B1 (ko) * 2021-01-27 2021-09-08 주식회사 에피바이오텍 콜라겐 유전자 또는 단백질을 포함하는 탈모의 예방 또는 개선용 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100841920B1 (ko) 2007-01-30 2008-06-27 제주대학교 산학협력단 탈모 방지 및 발모 개선 효과를 갖는 화장료 조성물
KR100841923B1 (ko) 2007-01-30 2008-06-27 제주대학교 산학협력단 탈모 방지 및 발모 개선 효과를 갖는 생약 조성물
KR102069184B1 (ko) 2019-06-28 2020-01-22 (주)미래씨티 신경줄기세포 추출물유래 bmp신호전달경로 억제 펩타이드 및 상기 펩타이드를 유효성분으로 포함하는 발모촉진 또는 탈모방지 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009161509A (ja) * 2008-05-21 2009-07-23 Kanazawa Univ Ｘｖｉｉ型コラーゲンに関する脱毛抑制剤、毛髪の脱色素化抑制剤
KR20120089236A (ko) * 2009-07-23 2012-08-09 아데란스 리서치 인스티튜트 인코포레이티드 트리코겐성 진피세포 검출/강화 방법과 세포 및 탈모 치료법에의 사용
KR20130117260A (ko) * 2012-04-18 2013-10-25 경북대학교 산학협력단 남성형 탈모 진단용 바이오마커 조성물 및 이를 이용한 진단 방법
JP2018168166A (ja) * 2016-01-12 2018-11-01 国立大学法人 東京医科歯科大学 脱毛および白毛化を抑制もしくは改善するための組成物ならびにその使用
KR102298460B1 (ko) * 2021-01-27 2021-09-08 주식회사 에피바이오텍 콜라겐 유전자 또는 단백질을 포함하는 탈모의 예방 또는 개선용 조성물

Also Published As

Publication number Publication date
KR102298460B1 (ko) 2021-09-08

Similar Documents

Publication Publication Date Title
WO2020218846A1 (fr) Composition de blanchiment de la peau comprenant un exosome de lait
WO2017123022A1 (fr) Exosome dérivé de cellules souches contenant une quantité importante de facteurs de croissance
WO2020204275A1 (fr) Composition pour la prévention de la chute des cheveux ou la stimulation de la pousse des cheveux
US11213513B2 (en) Compositions and methods for promoting hair growth with Mpc1 inhibitors
WO2010079978A2 (fr) Composition utilisable pour le traitement de l'inflammation faisant appel à des antigènes abh
WO2023055007A1 (fr) Peptide possédant une activité anti-vieillissement, et son utilisation
WO2021206335A1 (fr) Peptide pour la prévention ou le traitement de la perte des cheveux et utilisation correspondante
WO2022163989A1 (fr) Composition pour prévenir ou réduire la chute des cheveux, comprenant un gène ou une protéine de collagène
TW202102242A (zh) 余甘子萃取發酵物及其製備與應用
WO2022045635A1 (fr) Composition pour prévenir la chute des cheveux ou favoriser la pousse des cheveux comprenant un extrait de lagerstroemia indica en tant que principe actif
WO2021132970A1 (fr) Composition d'amélioration de l'élasticité de la peau et d'amélioration des rides comprenant des exosomes de lait
WO2021246755A1 (fr) Composition pour prévenir, soulager ou traiter une maladie métabolique, comprenant un inhibiteur de la phospholipase d2
WO2021002664A1 (fr) Composition pour la prévention, le soulagement ou le traitement d'un cancer
WO2019143145A1 (fr) Composition pour le traitement d'une inflammation cutanée, comprenant de la résolvine d2 en tant que principe actif
WO2021162463A9 (fr) Composition pour prévenir, traiter et soulager la dermatite atopique, comprenant un composé conjugué de flavone-resvératrol
WO2017146341A1 (fr) Composition pour le traitement des plaies, contenant de la daphnine, et son utilisation
WO2020222538A9 (fr) Composition pour la prévention ou le traitement de la chute des cheveux comprenant hapln1
US20250170150A1 (en) Olfactory receptor 2a4/7 agonist for promoting hair growth and improving aesthetic aspect
WO2014204229A2 (fr) Composition pharmaceutique pour la prévention ou le traitement de l'arthrite rhumatoïde, comprenant un peptide en tant que principe actif
WO2015030422A9 (fr) Composition pour accélérer la restauration des cheveux ou la croissance des cheveux, comprenant du 21-o-angéloylthéasapogénol e3
WO2025173928A1 (fr) Composition d'amélioration du cuir chevelu à l'aide de pseudomonas et de micrococcus et procédé de préparation associé
WO2023055006A1 (fr) Peptide ayant une activité anti-vieillissement, et son utilisation
WO2025084704A1 (fr) Nouveau peptide ayant une activité d'amélioration de l'état de la peau et ses utilisations
WO2025084702A1 (fr) Peptide ayant une activité d'amélioration de l'état de la peau et ses utilisations
WO2018056585A1 (fr) Composition de renforcement de la fonction de barrière cutanée comprenant un matériau favorisant l'expression de card18, et procédé de criblage de matériau favorisant l'expression de card18

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21923398

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21923398

Country of ref document: EP

Kind code of ref document: A1